Capricor Therapeutics (NASDAQ:CAPR) Hits New 1-Year High at $17.61

Capricor Therapeutics Inc (NASDAQ:CAPR) reached a new 52-week high during trading on Tuesday . The stock traded as high as $17.61 and last traded at $17.59, with a volume of 2190107 shares trading hands. The stock had previously closed at $15.21.

Analyst Ratings Changes

Several brokerages have issued reports on CAPR. Maxim Group lifted their target price on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Capricor Therapeutics in a research note on Tuesday, September 24th. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price target on shares of Capricor Therapeutics in a report on Monday, September 23rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $8.00 target price on shares of Capricor Therapeutics in a research note on Friday, September 20th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $22.60.

Capricor Therapeutics Trading Down 8.9 %

The business has a fifty day moving average price of $5.01 and a two-hundred day moving average price of $5.36. The firm has a market capitalization of $442.91 million, a PE ratio of -15.92 and a beta of 3.92.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.03). The company had revenue of $3.97 million during the quarter, compared to analysts’ expectations of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. On average, equities analysts forecast that Capricor Therapeutics Inc will post -1.14 earnings per share for the current fiscal year.

Insider Activity

In other news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the stock in a transaction that occurred on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the acquisition, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 12.00% of the company’s stock.

Hedge Funds Weigh In On Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. Marshall Wace LLP acquired a new stake in shares of Capricor Therapeutics in the second quarter valued at $426,000. Renaissance Technologies LLC raised its position in Capricor Therapeutics by 158.7% in the 2nd quarter. Renaissance Technologies LLC now owns 137,500 shares of the biotechnology company’s stock valued at $656,000 after purchasing an additional 84,350 shares in the last quarter. Main Street Financial Solutions LLC raised its position in Capricor Therapeutics by 37.5% in the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 7,500 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Capricor Therapeutics in the 2nd quarter valued at about $147,000. Finally, Bank of New York Mellon Corp grew its position in shares of Capricor Therapeutics by 12.8% during the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after buying an additional 9,040 shares in the last quarter. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.